^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
FG-3165
i
Other names: FG-3165, HFB200902, HFB-200902, HFB 200902, HFB9-2, FG3165, FG 3165, HFB92, HFB9 2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
HiFiBiO, Kyntra Bio
Drug class:
Galectin-9 inhibitor
Related drugs:
almost5years
[VIRTUAL] HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers (AACR 2021)
The serum levels of Gal-9 increased over time following the increase of hCD45+ AML cells. Further analysis to evaluate the effect of Gal-9 neutralization in AML progression after primary and secondary engraftment with HFB9-2 are currently ongoing.The data presented here provide evidence that neutralization of Gal-9 with HFB9-2 blocks key immunosuppressive mechanisms known to favor cancer progression and to limit the efficacy of current immunotherapies, and together with the data obtained in AML patient samples position Gal-9 neutralization as a promising anticancer approach.
PD(L)-1 Biomarker • IO biomarker
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD44 (CD44 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
|
FG-3165
Share via
